Results 1 to 10 of about 4,368 (233)

Disease-specific mortality in patients with acromegaly treated with pegvisomant: an ACROSTUDY analysis [PDF]

Endocrine Connections
Objective: Characterize disease-specific mortality rates in patients with acromegaly on pegvisomant and identify pertinent risk factors, including on-therapy insulin-like growth factor I (IGF-I) levels. Design: Retrospective cohort analysis of ACROSTUDY,
Nicholas A Tritos, Martin O Carlsson, Greisa Vila, Camilo Jimenez, Daria La Torre, Michael P Wajnrajch, Beverly M K Biller, Lissette Cespedes, Karen K Miller   +8 more
doaj   +4 more sources

Pegvisomant therapy in acromegalic patient resistant to other treatment: case report

Journal of Education, Health and Sport, 2022
Introduction: Acromegaly is a chronic, rare disorder resulting from growth hormone (GH) hypersecretion, usually caused by a pituitary adenoma. GH stimulates synthesis of insulin-like growth factor 1 (IGF-1), whom assay should be used as a screening test
Emilia Nowicka, Michał Obel, Piotr Dzikowski, Martyna Stefaniak, Zofia Pietrzak, Ewa Obel   +5 more
doaj   +4 more sources

Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation [PDF]

BMC Endocrine Disorders, 2009
Background Acromegaly, an orphan disease usually caused by a benign pituitary tumour, is characterised by hyper-secretion of growth hormone (GH) and insulin-like growth factor I (IGF-1).
Connock Martin J, Adi Yaser, Moore David J, Bayliss Sue   +3 more
doaj   +8 more sources

Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient [PDF]

, 2001
We describe the case of an acromegalic subject, who was the first patient ever treated with the GH receptor antagonist pegvisomant. Furthermore, in this particular patient, progression in tumor size was encountered during
Davis, R.J. (Robert), Janssen, J.A.M.J.L. (Joop), Lamberts, S.W.J. (Steven), Lely, A-J. (Aart-Jan) van der, Muller, A.F. (Alex), Scarlett, J.A. (John), Zib, K.A. (Kenneth)   +6 more
core   +5 more sources

Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency [PDF]

, 2001
Cardiovascular risk is increased in GH deficiency (GHD). GHD adults are frequently abdominally obese and display features of the metabolic syndrome. Otherwise healthy abdominally obese subjects have low GH levels and show features of
Hofland, L.J. (Leo), Janssen, J.A.M.J.L. (Joop), Lamberts, S.W.J. (Steven), Leebeek, F.W.G. (Frank), Lely, A-J. (Aart-Jan) van der, Muller, A.F. (Alex)   +5 more
core   +3 more sources

Cost-effectiveness analysis of second-line medical therapies in acromegaly: a real-life study [PDF]

Frontiers in Endocrinology
IntroductionAcromegaly is an uncommon disease with important comorbidity and economic cost. Although the pharmacological cost of second-line treatment for refractory acromegaly has been theoretically analyzed, real-life studies are needed.ObjectivesTo ...
Eva Venegas Moreno, Eva Venegas Moreno, Andrés Jiménez-Sánchez, Andrés Jiménez-Sánchez, Pablo Remón-Ruiz, Pablo Remón-Ruiz, Elena Dios, Elena Dios, Jaime Perea Cortés, Celia Hernández-Reina, David A. Cano, Alfonso Soto Moreno, Alfonso Soto Moreno   +12 more
doaj   +2 more sources

Impact of strict IGF1 control on quality-of-life scores in patients with acromegaly [PDF]

Frontiers in Endocrinology
ObjectiveExamine, in a real-world setting, whether strict normalization of modestly elevated insulin-like growth factor 1 (IGF1) results in clinical and health-related quality of life benefits in patients with acromegaly using an open-label, non ...
Chaitanya Gandhi, Marie-Claire Denis, Daniel Holmes, Juan Rivera, Stan van Uum, Shereen Ezzat, Constance Chik   +6 more
doaj   +2 more sources

Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies

BMC Endocrine Disorders, 2020
Background Acromegaly is a rare, chronic and severe disease. Drug therapy including somatostatin analogues (SAs), dopamine receptor agonists and growth hormone receptor antagonists (pegvisomant, PEG) are commonly used to treat patients who do not respond
Lingyun Ma, Daohuang Luo, Ting Yang, Songtao Wu, Min Li, Chaoyang Chen, Shuang Zhou, Lingyue Ma, Ye Wu, Ying Zhou, Yimin Cui   +10 more
doaj   +2 more sources

Pasireotide: successful treatment of a sparsely granulated tumour in a resistant case of acromegaly [PDF]

Endocrinology, Diabetes & Metabolism Case Reports, 2017
The granulation pattern of somatotroph adenomas is well known to be associated with differing clinical and biochemical characteristics, and it has been shown that sparsely granulated tumours respond poorly to commonly used somatostatin receptor ligands ...
W K M G Amarawardena, K D Liyanarachchi, J D C Newell-Price, R J M Ross, D Iacovazzo, M Debono   +5 more
doaj   +4 more sources

GH receptor polymorphisms guide second-line therapies to prevent acromegaly skeletal fragility: preliminary results of a pilot study [PDF]

Frontiers in Endocrinology
BackgroundSkeletal fragility is characterized by increased frequency of vertebral fractures (VFs) in acromegaly. Several trials were conducted to identify modifiable risk factors and predictors of VFs, with limited data on the prognostic role of GH ...
Sabrina Chiloiro, Sabrina Chiloiro, Flavia Costanza, Flavia Costanza, Antonella Giampietro, Antonella Giampietro, Amato Infante, Pier Paolo Mattogno, Pier Paolo Mattogno, Flavia Angelini, Flavia Angelini, Consolato Gullì, Liverana Lauretti, Liverana Lauretti, Mario Rigante, Alessandro Olivi, Alessandro Olivi, Laura De Marinis, Laura De Marinis, Francesco Doglietto, Francesco Doglietto, Antonio Bianchi, Antonio Bianchi, Alfredo Pontecorvi, Alfredo Pontecorvi   +24 more
doaj   +2 more sources